Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04080284 · ClinicalTrials.gov registry record · Phase 2
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
A Phase 2 study of Endometrial Cancer and Endometrial Carcinoma, sponsored by Northwell Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 6
- Study locations
NCT04080284 is a Phase 2 study of Endometrial Cancer and Endometrial Carcinoma that has completed, run by Northwell Health. The registered enrollment target is 22 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (96% lower). The trial reports 6 study locations across 2 states.
The verdict
NCT04080284, a Phase 2 study of Endometrial Cancer and Endometrial Carcinoma, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 6
- Study locations
Study Summary
Uterine serous carcinoma (USC) accounts for up to 40% of endometrial cancer-related deaths. Patients with USC share many genomic and clinical characteristics with patients who has serous ovarian cancer. The objective of this study is to evaluate the efficacy of maintenance Niraparib regimen in patients with advanced or platinum sensitive recurrent uterine serous carcinoma. Additionally, the investigators aim to further describe the safety of this regimen. The investigators hypothesize that Niraparib maintenance will be a well-tolerated treatment and show significant response in patients with uterine serous carcinoma.
Conditions Studied
Interventions
- DRUG Niraparib
Study Locations (6)
New York
- Imbert Cancer Center Northwell Health - Bay Shore
- Greenlawn Cancer Institute, Northwell Health - Greenlawn
- RJ Zuckerberg Cancer Hospital - New Hyde Park
- Cancer Institute at Lenox Hill - New York
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
- Rutgers NJ School of Medicine - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2019-12-30 |
| Est. Completion | 2025-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04080284
The ClinicalTrials.gov registry entry for NCT04080284 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Endometrial Cancer appearing as the primary indexed condition, and to 1 intervention - of which Niraparib is the first listed.
NCT04080284 reports 6 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT04080284 about?
NCT04080284 is a clinical study titled "Trial of Maintenance With Niraparib- Uterine Serous Carcinoma". Uterine serous carcinoma (USC) accounts for up to 40% of endometrial cancer-related deaths. Patients with USC share many genomic and clinical characteristics with patients who has serous ovarian cancer. The objective of this study is to evaluate the efficacy of maintenance Niraparib regimen in patie...
What is the current status of trial NCT04080284?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2019-12-30. Estimated completion is 2025-01-01.
What conditions does trial NCT04080284 study?
This clinical trial studies the following conditions: Endometrial Cancer, Endometrial Carcinoma, Uterine Serous Carcinoma, Cancer of the Endometrium, Papillary Serous Endometrial Carcinoma.
What interventions are being tested in trial NCT04080284?
The interventions under investigation include: Niraparib (DRUG).
Who is sponsoring clinical trial NCT04080284?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04080284 being conducted?
This trial has 6 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
RECRUITING · Phase 2
-
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
RECRUITING · Phase 2
-
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
RECRUITING · Phase 2
-
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.